Therefore, these equations cannot be used in patients with exogenous insulin use ( Despite important knowledge gaps in our understanding of IR in T1D, targeting IR in overweight/obese patients with T1D may decrease the risk of diabetes complications, contribute to weight loss, and improve glycemic control
Clinical Trial Results: The Numbers That Matter The Phase 2 clinical trial published in the New England Journal of Medicine provided the foundational data driving interest in Retatrutide
Yes, injecting GLP-1 medications above the belly button is generally acceptable and falls within FDA-approved guidelines for abdominal injection sites
Some researchers prioritize metabolic health markers
Consider combination approaches Some researchers explore stacking additional compounds with their primary GLP-1 agonist
GLP-1 receptor agonists work by mimicking the action of endogenous GLP-1, a hormone that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways
%201.png)
